[1]曾春琴,刘梦,周厚利,等.2型糖尿病患者血清FGF21、ADAM10水平与糖尿病视网膜病变关系研究[J].陕西医学杂志,2025,54(11):1532-1536.[doi:DOI:10.3969/j.issn.1000-7377.2025.11.018]
　ZENG Chunqin,LIU Meng,ZHOU Houli,et al.Relationship between serum FGF21,ADAM10 levels and diabetic retinopathy in patients with type 2 diabetes mellitus[J].,2025,54(11):1532-1536.[doi:DOI:10.3969/j.issn.1000-7377.2025.11.018]
点击复制

2型糖尿病患者血清FGF21、ADAM10水平与糖尿病视网膜病变关系研究

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
54
期数:
2025年11期
页码:
1532-1536
栏目:
临床检验
出版日期:
2025-11-05

文章信息/Info

Title:
Relationship between serum FGF21,ADAM10 levels and diabetic retinopathy in patients with type 2 diabetes mellitus
作者:
曾春琴; 刘梦; 周厚利; 黄娇; 胡高铭
（重庆市江津区中心医院眼科，重庆 402260）
Author(s):
ZENG Chunqin; LIU Meng; ZHOU Houli; HUANG Jiao; HU Gaoming
（Department of Ophthalmology,Jiangjin Central Hospital,Chongqing 402260,China）
关键词:
2型糖尿病; 成纤维细胞生长因子21; 解整合素样金属蛋白酶10; 糖尿病视网膜病变; 影响因素; 诊断价值
Keywords:
Type 2 diabetes mellitus; Fibroblast growth factor 21; Disintegrin and metalloproteinase 10; Diabetic retinopathy; Influencing factors; Diagnostic value
分类号:
R 587.1
DOI:
DOI:10.3969/j.issn.1000-7377.2025.11.018
文献标志码:
A
摘要:
目的：探讨2型糖尿病（T2DM）患者血清成纤维细胞生长因子21（FGF21）、解整合素样金属蛋白酶10（ADAM10）水平与糖尿病视网膜病变（DR）的关系。方法：选取T2DM患者90例为疾病组，根据是否发生DR分为DR组（37例）和NDR组（53例）。另选取同期体检健康者76例为对照组。采用ELISA法检测血清FGF21、ADAM10水平；多因素Logistic回归分析T2DM患者DR发生的影响因素；绘制受试者工作特征（ROC）曲线分析血清FGF21、ADAM10对T2DM患者DR的诊断价值。结果：疾病组血清FGF21、ADAM10水平高于对照组（均P＜0.05）。DR组患者T2DM病程长于NDR组，合并高血压比例高于NDR组（均P＜0.05）。与NDR组比较，DR组血清FGF21、ADAM10水平升高（均P＜0.05）。血清FGF21、ADAM10是T2DM患者DR发生的影响因素（均P＜0.05）。血清FGF21、ADAM10联合诊断的曲线下面积（AUC）高于两者单独诊断的AUC（均P＜0.05）。结论：DR患者血清FGF21、ADAM10水平升高，两者联合检测对T2DM患者DR有较高的诊断价值。
Abstract:
Objective:To investigate the relationship between serum fibroblast growth factor 21 (FGF21),disintegrin and metalloproteinase 10 (ADAM10) levels and diabetic retinopathy (DR) in patients with type 2 diabetes mellitus (T2DM).Methods：A total of 90 patients with T2DM were selected as the disease group,which was further divided into the DR group (37 cases) and the non-DR (NDR) group (53 cases) based on the presence or absence of DR.In addition,76 healthy individuals who underwent physical examination during the same period were selected as the control group.The levels of serum FGF21 and ADAM10 were detected by ELISA.Multivariate logistic regression analysis was used to identify the influencing factors of DR in T2DM patients.ROC curves were plotted to analyze the diagnostic value of serum FGF21 and ADAM10 for DR in T2DM patients.Results:The levels of serum FGF21 and ADAM10 in the disease group were higher than those in the control group (all P<0.05).The duration of T2DM in the DR group was longer than that in the NDR group,and the proportion of patients with hypertension was higher in the DR group than in the NDR group (all P<0.05).Compared with the NDR group,the levels of serum FGF21 and ADAM10 were elevated in the DR group (all P<0.05).Serum FGF21 and ADAM10 were identified as influencing factors for the occurrence of DR in T2DM patients (all P<0.05).The AUC for the combined diagnosis of serum FGF21 and ADAM10 was higher than the AUC for either marker alone (all P<0.05).Conclusion:The levels of serum FGF21 and ADAM10 are elevated in patients with DR,and the combined detection of the two has a higher diagnostic value for DR in T2DM patients.

参考文献/References:

[1]高珊,乔媛,董春萍.2型糖尿病视网膜病变患者血清Notch1、Notch3和JAG1水平变化及检测意义[J].陕西医学杂志,2025,54(5):688-692.
[2]TEO Z L,THAM Y C,YU M,et al.Global prevalence of diabetic retinopathy and projection of burden through 2045:Systematic review and meta-analysis[J].Ophthalmology,2021,128(11):1580-1591.
[3]刘明珠,管怀进.糖尿病前期和糖尿病视网膜病变临床前期的视网膜改变[J].眼科学报,2023,38(6):454-460,489.
[4]张永康,葛吉林.胰激肽原酶联合微脉冲治疗增殖性糖尿病视网膜病变疗效及对患者视网膜功能、炎症因子的影响[J].陕西医学杂志,2023,52(2):204-207.
[5]JIN S,XIA N,HAN L.Association between serum fibroblast growth factor 21 level and sight-threatening diabetic retinopathy in Chinese patients with type 2 diabetes[J].BMJ Open Diabetes Res Care,2021,9(1):e002126.
[6]JIANG Y,ZHANG W,XU Y,et al.Relationship of fibroblast growth factor 21,Klotho,and diabetic retinopathy:A meta-analysis[J].Front Endocrinol (Lausanne),2024,15:1390035.
[7]SIKORA-SKRABAKA M,WALKIEWICZ K W,NOWAKOWSKA-ZAJDEL E,et al.ADAM10 and ADAM17 as biomarkers linked to inflammation,metabolic disorders and colorectal cancer[J].Curr Issues Mol Biol,2022,44(10):4517-4527.
[8]ABU EL-ASRAR A M,NAWAZ M I,AHMAD A,et al.Evaluation of proteoforms of the transmembrane chemokines CXCL16 and CX3CL1,their receptors,and their processing metalloproteinases ADAM10 and ADAM17 in proliferative diabetic retinopathy[J].Front Immunol,2021,11:601639.
[9]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2017年版)[J].中华糖尿病杂志,2018,10(1):4-67.
[10]中华医学会眼科学会眼底病学组.我国糖尿病视网膜病变临床诊疗指南(2014年)[J].中华眼科杂志,2014,50(11):851-865.
[11]KANG Q,YANG C.Oxidative stress and diabetic retinopathy:Molecular mechanisms,pathogenetic role and therapeutic implications[J].Redox Biol,2020,37:101799.
[12]张慧,张玉福,代婷,等.基于心主血脉藏神理论探讨糖尿病视网膜病变的病因病机[J].陕西中医,2025,46(1):76-79.
[13]ZHANG J,ZHANG J,ZHANG C,et al.Diabetic macular edema:Current understanding,molecular mechanisms and therapeutic implications[J].Cells,2022,11(21):3362.
[14]LI H,LIU X,ZHONG H,et al.Research progress on the pathogenesis of diabetic retinopathy[J].BMC Ophthalmol,2023,23(1):372.
[15]刘爱华,白晶,王娜,等.2型糖尿病视网膜病变患者血清APN、SUA及MLR水平的变化及诊断价值研究[J].标记免疫分析与临床,2024,31(3):414-420.
[16]LIN K Y,HSIH W H,LIN Y B,et al.Update in the epidemiology,risk factors,screening,and treatment of diabetic retinopathy[J].J Diabetes Investig,2021,12(8):1322-1325.
[17]SZCZEPANSKA E,GIETKA-CZERNEL M.FGF21:A novel regulator of glucose and lipid metabolism and whole-body energy balance[J].Horm Metab Res,2022,54(4):203-211.
[18]蔡丽英,罗钢.糖尿病视网膜病变患者血清趋化素和成纤维细胞生长因子21的表达及意义[J].实用临床医药杂志,2021,25(16):76-80.
[19]司捷,陈云霞,高倩.miRNA-27、FGF21及AGE在2型糖尿病血清中的表达及其与微血管并发症的相关性[J].临床和实验医学杂志,2024,23(7):710-714.
[20]董靖,张佳佳,刘敏,等.2型糖尿病合并脑梗死患者血清FGF21、RAGE、DKK1表达情况及其意义[J].临床和实验医学杂志,2024,23(12):1237-1241.
[21]PIWKOWSKA A,RACHUBIK P,TYPIAK M,et al.ADAM10 as a major activator of reactive oxygen species production and klotho shedding in podocytes under diabetic conditions[J].Biochem Pharmacol,2024,225:116328.
[22]SMITH T M JR,THARAKAN A,MARTIN R K.Targeting ADAM10 in cancer and autoimmunity[J].Front Immunol,2020,11:499.
[23]郭永真,李昱儒,赵楠.血清ADAM10和DPP-4水平对糖尿病视网膜病变的诊断价值[J].微循环学杂志,2024,34(2):87-90.
[24]VAN MEENEN D,DOEGE A,ALEFELD E,et al.ADAM10 and ADAM17-novel players in retinoblastoma carcinogenesis[J].Int J Mol Sci,2022,23(20):12621.
[25]ALLI-SHAIK A,QIU B,LAI S L,et al.System-wide vitreous proteome dissection reveals impaired sheddase activity in diabetic retinopathy[J].Theranostics,2022,12(15):6682-6704.

相似文献/References:

[1]李艳艳,贾 伟△.24h动态心电图在2型糖尿病合并冠心病患者心律诊断中的价值分析[J].陕西医学杂志,2019,(1):61.
[2]郭向东,马 波△.2型糖尿病患者血清胰岛素水平与骨代谢关联研究*[J].陕西医学杂志,2019,(1):77.
　GUO Xiangdong,MA Bo..Association between serum insulin level and bone metabolismin patients with type 2 diabetes mellitus[J].,2019,(11):77.
[3]刘毅龙,陈鹏宇,雷 江,等.SGLT2抑制剂在2型糖尿病合并心血管疾病治疗中的应用研究进展[J].陕西医学杂志,2019,(3):407.
[4]姚爱红.利拉鲁肽治疗2型糖尿病效果及对患者血脂、颈动脉内膜中层厚度的影响[J].陕西医学杂志,2019,(4):518.
　YAO Aihong..Effect of liraglutide on type 2 diabetes mellitus in patients with blood lipids and carotid intimamedia thickness[J].,2019,(11):518.
[5]李忆琴,吴礼凤,余晓君,等.中年2型糖尿病患者病程和HbA1c水平与认知功能相关性研究*[J].陕西医学杂志,2019,(6):722.
[6]徐 琳,贾睿博△,宋民喜,等.颗粒蛋白前体与糖尿病肾病关系探讨*[J].陕西医学杂志,2019,(8):1024.
[7]王荣锋,郁 昊,蒋新建.老年糖尿病患者血清25羟维生素D水平与骨质疏松相关性研究[J].陕西医学杂志,2019,(8):1032.
　WANG Rongfeng,YU Hao,JIANG Xinjian..The relationship between serum 25 hydroxy vitamin D and osteoporosis in elderly diabetic patients[J].,2019,(11):1032.
[8]王 荣,贾爱华,刘新艳 ,等.IGF1及其相关性因素对2型糖尿病并发骨质疏松的影响研究[J].陕西医学杂志,2019,(9):1163.
　WANG Rong,JIA Aihua,LIU Xinyan,et al.The effect of IGF1 and its related factors in type 2 diabetes complicated with osteoporosis[J].,2019,(11):1163.
[9]贾睿博,徐 琳△.2型糖尿病患者下肢血管病变相关危险因素调查研究[J].陕西医学杂志,2019,(11):1567.
[10]郭建强,赵俊宏,张分队,等.2型糖尿病视网膜病变患者血清HbA1c、CysC检测及临床意义*[J].陕西医学杂志,2020,49(5):619.
　GUO Jianqiang,ZHAO Junhong,ZHANG Fendui,et al.Changes of serum HbA1c and CysC in patients with type 2 diabetic retinopathy and their clinical significance[J].,2020,49(11):619.

备注/Memo

备注/Memo:
重庆市自然科学基金资助面上项目（CSTB2023NSCQ-MSX0639）
更新日期/Last Update: 2025-11-04